Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?
Open Access
- 16 February 2022
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 17 (1) , 1-7
Abstract
Background: Neurotrophic keratopathy (NK) is a rare, degenerative ocular disease characterized by reduction or loss of corneal sensitivity and development of non-healing corneal epithelial defects and ulcers. Cenegermin, a recombinant human nerve growth factor (rhNGF) eye drop solution, is the first drug approved for the treatment of NK. The aim of our study is to evaluate the long-term efficacy of this innovative topical treatment in patients with NK. Methods: Retrospective, consecutive, observational case series study from a single-center setting (Department of Sense Organs, University Sapienza of Rome, Rome, Italy). 18 patients with diagnosis of stage 2 or 3 NK, treated with Cenegermin 20 mcg/ml eye drops were followed for up to 48 months. Recurrence of lesion during follow-up was evaluated at 12, 24, 36, and 48 months. In addition, corneal sensitivity, Schirmer tear test, and visual acuity (VA) were recorded at baseline, end of treatment, and at 12, 24, 36, and 48 months. Results: Three patients experienced recurrence of persistent epithelial defects (PEDs) within 12 months and one patient experienced recurrence of a corneal ulcer within 36 months. Corneal sensitivity was significantly improved at all timepoints (P < 0.05). Significant improvements in visual acuity and tear production were seen at the completion of treatment as well as at 12, 24, and 36 months (P < 0.05) when compared to baseline. Conclusions: A single 8-week treatment regimen of Cenegermin eye drops has clinical efficacy that can persist for up to 48 months. The long-term clinical utility of treatment with Cenegermin for NK was demonstrated through the low rate of lesion recurrence along with improvements in corneal sensitivity and tear production.Keywords
This publication has 18 references indexed in Scilit:
- Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic KeratitisOphthalmology, 2018
- Understanding the Pathogenesis of Neurotrophic Keratitis: The Role of Corneal NervesJournal of Cellular Physiology, 2016
- Congenital Corneal Anesthesia and Neurotrophic Keratitis: Diagnosis and ManagementBioMed Research International, 2015
- Diagnosis and management of neurotrophic keratitisClinical Ophthalmology, 2014
- Safety and Pharmacokinetics of Escalating Doses of Human Recombinant Nerve Growth Factor Eye Drops in a Double-Masked, Randomized Clinical TrialBioDrugs, 2013
- Nerve growth factor therapy for corneal diseaseCurrent Opinion in Ophthalmology, 2012
- Corneal nerves: structure, contents and functionExperimental Eye Research, 2003
- Topical treatment with nerve growth factor for neurotrophic keratitisOphthalmology, 2000
- Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcersOphthalmology, 1999
- Topical Treatment with Nerve Growth Factor for Corneal Neurotrophic UlcersNew England Journal of Medicine, 1998